Questions for the Advisory Committee for NDA[removed]

First Page		Document Content
Date: 2007-09-04 07:18:02 Organofluorides Amides Merck Oxadiazoles Raltegravir Antiretroviral drug HIV Zidovudine Integrase Chemistry Organic chemistry Integrase inhibitors		Questions for the Advisory Committee for NDA[removed] Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 12,87 KB Share Document on Facebook

	Switching between raltegravir resistance pathways analyzed by deep sequencing Rithun Mukherjeea, Shane T. Jensenb, Frances Malea, Kyle Bittingera, Richard L. Hodinkac,d, Michael D. Millere and Frederic D. Bushmana Object DocID: 1rImN - View Document
	12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box DocID: 1qIwe - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (avrilANRS 160 RalFE Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir pendant l DocID: 1lV9R - View Document
	ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL DocID: 1fNy0 - View Document
	Merck Sharp Dohme Haarlem raltegravir Isentress HIV aanbiedingsbrief rapporten ministerPOVOOPEN.DOC DocID: 1ey1D - View Document